Hikal Ltd has received a Certificate of GMP Compliance from Swissmedic for its Bengaluru API facility. This approval validates the site's manufacturing standards under the EU-Switzerland Mutual Recognition Agreement, enabling the company to expand its reach across European and other highly regulated global pharmaceutical markets.
Hikal API Facility Gains Swissmedic GMP Certification
- Certification: GMP Compliance confirmed by Swissmedic for Bengaluru API site.
- Scope: Compliance with Mutual Recognition Agreement between the EU and Switzerland.
Reader Takeaway: Regulatory nod unlocks new European market opportunities while validating high-quality standards across Hikal's global API operations.
What just happened
Hikal Ltd has received a formal Certificate of GMP Compliance from Swissmedic, the Swiss Agency for Therapeutic Products. The certification pertains to the company’s Active Pharmaceutical Ingredient (API) manufacturing site in Bengaluru. This achievement confirms that the facility strictly adheres to the Good Manufacturing Practice (GMP) requirements established under the Mutual Recognition Agreement between the European Union and Switzerland.
Why this matters
Securing this certification is a strategic win for Hikal as it seeks to diversify its geographic presence. By meeting the stringent quality standards of Swissmedic, the facility gains enhanced credibility with potential and existing clients in Europe. The approval effectively removes regulatory barriers for shipping API products to these high-value regions.
The backstory
The Bengaluru facility has been consistently building its regulatory profile. Prior to this Swissmedic grant, the site successfully navigated inspections by Brazil's ANVISA and Japan's PMDA. This track record suggests a sustained focus on international quality standards, which is vital for an API player aiming for a larger share in regulated markets.
Management Commentary
Sameer Hiremath, Chairman & Managing Director of Hikal Limited, noted that the certification is a validation of the facility's quality systems. He added that the development is a cornerstone for the company’s strategy to deepen its footprint in Europe and other regulated international territories, emphasizing that compliance remains central to maintaining long-term partnerships with global customers.
What to track next
Investors should monitor the impact of this certification on future export volumes and new client acquisitions in European markets throughout the coming fiscal quarters.